These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29552210)

  • 1. Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.
    Lu H; Chen B; Qin J; Xie F; Han N; Huang Z
    Oncol Lett; 2018 Apr; 15(4):5799-5802. PubMed ID: 29552210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
    Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
    Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
    Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
    Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
    Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
    Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review.
    Chen S; He Y; Liu J; Chen X; Yu J; Li W; Chen B; Sun C; Zhou C
    Onco Targets Ther; 2019; 12():11305-11311. PubMed ID: 31908495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of Lung Squamous Cell Carcinoma to Small Cell Lung Cancer After Immunotherapy Resistance: A Case Report.
    Wang D; Ye W; Chen D; Shi Q; Ma D
    Cancer Manag Res; 2023; 15():803-808. PubMed ID: 37583652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.
    Hirakawa H; Komiya K; Nakashima C; Ogusu S; Nakamura T; Tanaka M; Takahashi K; Egashira Y; Kai K; Kimura S; Sueoka-Aragane N
    Ann Transl Med; 2018 Dec; 6(23):464. PubMed ID: 30603652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report.
    Lee S; Joo J; Kwak M; Sohn K; Chon S
    Onco Targets Ther; 2018; 11():3943-3947. PubMed ID: 30022837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.
    Jin CB; Yang L
    World J Clin Cases; 2021 Jun; 9(18):4617-4626. PubMed ID: 34222428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma.
    Mao X; Liu J; Hu F; Niu Y; Pan F; Fu X; Jiang L
    Cancer Manag Res; 2022; 14():1293-1302. PubMed ID: 35386183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.
    Ahn S; Hwang SH; Han J; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ; Park WY
    J Pathol Transl Med; 2016 Jul; 50(4):258-63. PubMed ID: 27160687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report.
    Wang Y; Shen YH; Ma S; Zhou J
    Oncol Lett; 2015 Sep; 10(3):1575-1578. PubMed ID: 26622712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report.
    Zhai SS; Yu H; Gu TT; Li YX; Lei Y; Zhang HY; Zhen TH; Gao YG
    World J Clin Cases; 2020 Sep; 8(17):3841-3846. PubMed ID: 32953862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
    Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
    Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.
    Kim WJ; Kim S; Choi H; Chang J; Shin HJ; Park CK; Oh IJ; Kim KS; Kim YC; Choi YD
    Thorac Cancer; 2015 Nov; 6(6):800-4. PubMed ID: 26557922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.